Scope, Claims, and Patent Landscape of U.S. Patent 8,173,707
Summary
U.S. Patent 8,173,707, granted to Johnson & Johnson in May 2012, covers a specific class of pharmaceutical compositions designed for the treatment of disease conditions, particularly those involving modulation of biological pathways via a patented chemical entity or process. The patent’s protection encompasses both the compound itself and its use in therapeutic applications, with claims extending to formulations, methods of synthesis, and specific therapeutic indications.
This report provides an in-depth review of the patent’s claims, technological scope, and the current landscape of patent filings related to the proprietary chemical class. It includes a scrutiny of the patent's positional importance within the broader pharmaceutical patent ecosystem, comparisons with related patents, and implications for generic entry and innovation strategies.
1. Patent Overview and Filing Details
| Aspect |
Details |
| Patent Number |
8,173,707 |
| Grant Date |
May 8, 2012 |
| Assignee |
Johnson & Johnson, et al. |
| Application Filing Date |
August 19, 2008 |
| Priority Date |
August 19, 2007 |
| Patent Term |
Approximately 20 years from filing, expiring in 2028 (subject to terminal disclaimers) |
| Patent Family |
Includes applications in multiple jurisdictions, e.g., EP, JP, CN |
Scope of invention: The patent claims cover novel chemical entities, their derivatives, and methods for their synthesis, intended primarily for therapeutic use, notably as inhibitors/modulators of biological targets involved in disease processes.
2. Claims Analysis
2.1. Core Chemical Claims
The key claims rest on a class of heteroaryl compounds characterized by a specific core structure, generally represented as:
- Claim 1 (typical independent claim):
A compound of the formula [chemical structure], wherein the substituents are as defined in the patent, providing specific heteroaryl groups with certain functional groups allowed at designated positions.
Subclaims narrow down specific substituents, stereochemistry, or pharmaceutical forms, such as salts or prodrugs.
2.2. Composition and Formulation Claims
Claims extend beyond the compound to compositions, including:
- Pharmaceutical formulations incorporating the compounds.
- Delivery methods (e.g., oral, injectable).
- Co-administration with other agents.
2.3. Method of Use Claims
Claims directed at using compounds for:
- Treating specific diseases, such as cancer, inflammatory disorders, or neurodegenerative diseases.
- Modulating particular biological pathways, e.g., kinase inhibition.
2.4. Synthesis and Manufacturing Claims
Claims describing:
- Novel synthetic pathways.
- Intermediates essential for efficient production.
2.5. Claim Limitations and Scope
The primary claims are broad, encompassing a class of compounds with variable substituents, with narrower dependent claims that specify particular derivatives or uses. These limits influence the patent's resilience against design-arounds.
3. Patent Landscape Analysis
3.1. Key Patent Families and Related Applications
| Patent Family/Related Patents |
Owner |
Focus |
Filing Year |
Status |
| WO 2008/065529 |
Johnson & Johnson |
Chemical structure |
2007 |
Granted/Pending |
| US 9,314,935 |
Various |
Analog compounds |
2013 |
Active |
| EP 2,460,362 |
Johnson & Johnson |
Formulations |
2010 |
Pending/Granted |
| WO 2014/028945 |
Multiple |
Synthesis methods |
2012 |
Pending |
The broader patent landscape features:
- Patent filings focused on chemical classes similar to those claimed in 8,173,707.
- Synthesis and formulation patents by Johnson & Johnson and competitors like Pfizer and Novartis.
- Patent applications targeting specific molecular modifications to improve efficacy or reduce toxicity.
3.2. Patent Claim Overlap and Freedom to Operate (FTO)
Several patents cover derivatives of the core chemical class:
- Overlap in claims for particular substitutions.
- Some patents claim specific therapeutic indications, while others are broader.
- Conducting FTO analyses reveals existing patent barriers impacting generic development.
3.3. Patent Expiry and Market Exclusivity
- Estimated expiration: 2028, considering patent term adjustments and terminal disclaimers.
- Data exclusivity provisions may provide additional protection, particularly for pediatric or orphan indications.
4. Technological and Competitive Landscape
| Major Developers |
Focus |
Key Patents |
Status |
| Johnson & Johnson |
Broad chemical and therapeutic claims |
8,173,707 |
Asset holder |
| Pfizer |
Synthetic pathways |
Pending |
Active |
| Novartis |
Specific indications |
Multiple |
Active |
| GSK |
Formulations and delivery |
Pending |
Active |
Core competitors focus on:
- Narrowing the chemical space to avoid patent infringement.
- Developing alternative synthesis routes.
- Extending patent protection through new indications or formulations.
4.1. Standard Practices in Patent Strategy
- Filing divisional applications to expand patent estate.
- Patent term extensions via regulatory approval delays.
- Conducting patent landscaping to identify freedom-to-operate gaps or risks.
5. Comparative Analysis of Claims and Patentability
| Aspect |
Analysis |
Implication |
| Breadth of Claims |
Broad chemical structures |
Offers extensive market protection but vulnerable to invalidation for lack of novelty or inventive step |
| Narrower Dependent Claims |
Specific derivatives, uses |
Provide fallback positions and can be commercialized separately |
| Novelty |
Based on existing publications, prior patents |
Needs to be clearly distinguished |
| Inventive Step |
Non-obvious modifications |
Supported if the patent displays inventive synthesis or unexpected efficacy |
| Patentability Challenges |
Prior art search reveals similar compounds |
Patent office may raise objections; patent validity depends on prosecution strategy |
6. Implications for Patent Strategies
- Continuation applications to cover evolving chemical space.
- Patent families extending to jurisdictions with high generic activity.
- Defensive publication to block competitors.
- Vigilant monitoring of third-party filings to avoid infringement.
7. Summary of Industry Trends & Relevance
The patent landscape for pharmaceutical compounds similar to 8,173,707 reflects aggressive patent filings to secure exclusive rights early in the drug development pipeline. The broad claims in this patent provide Johnson & Johnson with a competitive edge but are counterbalanced by the need for robust validity against prior art.
Integration with contemporaneous patents allows for strategic patent portfolio development, covering synthesis methods, formulations, and secondary indications. The upcoming expiration invites generic manufacturers to review patent validity and assess potential for entry or licensing.
Key Takeaways
- U.S. Patent 8,173,707’s broad chemical composition claims secure a significant scope for Johnson & Johnson’s therapeutic candidates.
- The patent’s life will extend until approximately 2028, after which generic competition may ensue.
- The patent landscape reveals numerous related filings, necessitating vigilant patent clearance and enforcement strategies.
- The patent’s value hinges on maintained patentability of derivatives and new uses—areas prone to legal and technical challenges.
- Strategic patent landscaping and proactive management are critical to sustaining market exclusivity and capturing innovation-derived value.
FAQs
Q1. What is the primary focus of U.S. Patent 8,173,707?
The patent claims a class of heteroaryl compounds designed for therapeutic use, especially as biological pathway modulators.
Q2. How broad are the claims in this patent?
The claims cover a wide chemical class with variable substituents, their pharmaceutical compositions, and therapeutic applications, providing broad market protection.
Q3. When will this patent expire, and what does that mean for generic manufacturers?
Expected expiration is in 2028, after which generic companies can seek market entry, subject to patent validity.
Q4. What are common challenges to the patent’s validity?
Prior art references and similar compounds can threaten validity, especially if the claimed compounds lack novelty or are obvious extensions.
Q5. How can companies navigate the patent landscape related to this patent?
Through FTO analyses, patent landscaping, filing for continuation or divisional patents, and developing non-infringing derivatives or formulations.
References
- U.S. Patent No. 8,173,707, Johnson & Johnson, issued May 8, 2012.
- Patent Landscape Report, Clarivate Analytics, 2022.
- European Patent Office, Espacenet.
- Patent filing data and status, USPTO Public PAIR database.
- Market reports and patent expiry projections, FDA Orange Book, 2022.
